BeiGene, a global biotechnology company, is entering a new phase as it continues to build its US presence. Its new facility in New Jersey will provide state-of-the-art commercial-stage US biologic pharmaceutical manufacturing, clinical development capabilities and late-stage research.

“Adding these manufacturing and R&D capabilities in the US is a major step toward fulfilling our vision to create impactful medicines that will be affordable and accessible to far more cancer patients around the world,” said John V Oyler, co-founder, chairman and CEO of BeiGene.

The new campus will have approximately 37,000m2 of dedicated commercial-stage biologic pharmaceutical manufacturing space with the ability to add 55,000m2 more over time. First announced in 2021, BeiGene’s investment in this project is expected to total approximately $700m. Construction is expected to be complete in 2024.

“Serving the needs of cancer patients requires a focus on the big picture without losing sight of the needs of the individual patient,” said Amy J Sutton, CEO of Crossroads4Hope, a non-profit organisation committed to transforming the cancer experience for patients and their families across New Jersey. “While BeiGene’s new centre will undoubtedly address that big picture by developing and manufacturing new medicines, as advocates we truly appreciate the company’s partnership in supporting and listening to people affected by cancer.”

As construction continues, BeiGene is already beginning to hire, with nearly 100 employees expected by the end of 2023 and more to come once construction is complete. The company is actively working with local business groups, educational institutions and industry associations to tap into the community’s deep life sciences talent pool.

“Hopewell Township is pleased to see BeiGene following through with its plans to build a state-of-the-art centre here,” said Hopewell Township mayor Michael Ruger. “We are excited that our talented and experienced workforce will have the opportunity to help BeiGene develop and manufacture life-saving medicines.”